

Predicting Anxiety and Depression Among Patients With COVID-19 in Concentrated Isolation at Medical Camps in Vietnam: A Descriptive Cross-Sectional Study

OPEN ACCESS

Edited by:

Marco Grados, Johns Hopkins Medicine, United States

Reviewed by:

Wen-Jun Tu, Chinese Academy of Medical Sciences and Peking Union Medical College, China Jelena Vrublevska, Riga Stradiņš University, Latvia

*Correspondence:

Le Van Truong bs.vantruong@gmail.com †These authors share first authorship

Specialty section:

This article was submitted to Anxiety and Stress Disorders, a section of the journal Frontiers in Psychiatry

Received: 27 November 2021 Accepted: 20 April 2022 Published: 31 May 2022

Citation:

Trang VTT, Huynh KLA, Truong HT, Nguyen HT, Hoang GT, Dao DQ, Van Vu U, Hassan Z, Nguyen MNH and Truong LV (2022) Predicting Anxiety and Depression Among Patients With COVID-19 in Concentrated Isolation at Medical Camps in Vietnam: A Descriptive Cross-Sectional Study. Front. Psychiatry 13:823586. doi: 10.3389/fpsyt.2022.823586 Vu Thi Thu Trang^{1†}, Khoa Le Anh Huynh^{2†}, Huyen Thi Truong³, Hue Thi Nguyen³, Giang Truong Hoang⁴, Dat Quang Dao⁵, Ut Van Vu³, Zair Hassan⁶, My Ngoc Ha Nguyen² and Le Van Truong^{3*}

¹ Acupuncture Department, National Hospital of Traditional Medicine, Hanoi, Vietnam, ² Department of Biostatistics, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States, ³ Traditional Medicine Hospital, Ministry of the Public Security, Hanoi, Vietnam, ⁴ U Buou Hospital, Bac Giang City, Vietnam, ⁵ Son Uyen General Hospital, Bac Giang City, Vietnam, ⁶ Lady Reading Hospital, Peshawar, Pakistan

Introduction: This study aims to assess the requirement for anxiety and depression treatment for patients with coronavirus disease 2019 (COVID-19) in medical camps in Bac Giang province, Vietnam. This information can help improve the government policy to reduce anxiety and depression in patients with COVID-19.

Methods: A total of patients with 427 COVID-19 participated in the survey conducted from 5 to 15 June 2021 in Bac Giang province. The survey included 17 questions about the general characteristics of the patients, 15 questions to assess common COVID-19 symptoms, the Patient Health Questionnaire-9 (PHQ-9), and General Anxiety Disorder-7 (GAD-7) scores, and four questions to assess hospital reviews, including facilities, food, medical staff, and living conditions. Logistics regression analyses were conducted to assess the association between COVID-19 symptoms and high anxiety and depression (HAD) status.

Results: A logistic regression analysis evaluated the risk factors in need of intervention. Our study showed that lower hospital review scores (odd ratio = 0.98; 95% confident interval = 0.97-0.99) were found to be a risk needing intervention. It was also identified that older patients (odd ratio = 1.1; 95% confident interval = 1.03-1.18), women (odd ratio = 1.31; 95% confident interval = 1.09-1.31), patients who were primary income earners in the family (odd ratio = 1.16; 95% confident interval = 1.06-1.21), and patients who had headaches (odd ratio = 1.17; 95% confident interval = 1.06-1.21), were risk factors for HAD status.

1

Conclusion: Our research shows that every 10-year age increase was associated with a 10% increase in the likelihood of HAD status. Study subjects being primary income earners were also associated with a 15% increased risk of having HAD status. This study showed that a decrease in family income due to COVID-19 caused an increase in high-level anxiety/depression status.

Keywords: depression, COVID-19, anxiety, multiple logistics regression, medical camps

INTRODUCTION

On 1 December 2019, the first patient infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China, and was described with strange pneumonia (1, 2). While complex transmission mechanisms had often been mentioned for SARS-CoV-2, such as surface contact and fecal-oral or airborne transmission (3, 4), the main transmission would in fact be direct human-to-human (3, 4). Four months after the first infected patients, SARS-CoV-2 had spread globally and became a humanitarian disaster (5, 6).

Although the first COVID-19 death occurred on 22 January, 2020, in Wuhan, China, the Vietnamese government immediately took strong measures to control the situation. Early decisions included social distancing and the isolation of all infected and suspected cases. This allowed Vietnam to control the average daily number of infections to about 6.2 cases. Centralized isolation measures significantly reduced the spread of infection sources. Bac Giang province was under such control for more than 4 months. The fourth wave of COVID-19 at the end of April 2021, consisting of the Delta variant of the virus, caused an outbreak in Bac Giang province. According to a report, authorities were required to isolate 5,779 F0 patients who were inflected by COVID-19, and 43,469 F1 cases who were in close contact with infected patients for 14 days (7). With merely nine

hospitals in the province, only patients with severe symptoms were admitted. To meet the need for isolation, 326 medical camps were established (7), making use of sports halls, schools, factories, and so forth. However, these camps had inadequate facilities and limited living conditions. In addition, evidence showed that isolation were associated with psychological effects (8, 9). Our study was designed to assess the status of anxiety and depression in the medical camps in Bac Giang. Such an assessment could provide information regarding factors influencing the situation, which, in turn, could improve government policy to reduce depression and anxiety in patients with COVID-19.

MATERIALS AND METHODS

Study Design and Participants

This study with a cross-sectional descriptive study was conducted in medical camps in Bac Giang province from 5 to 15 June 2021. The study excluded participants in Bac Giang Province Hospital, patients under 18 years old, and patients who refuse to download the ZALO app. We randomly selected isolated patients and conducted an online survey through Google Forms. After that, we communicated with the patients through the ZALO app to track their symptoms.




TABLE 1 | Sociodemographic characteristics by anxiety and depression status.

	Low anxiety and depression $N = 253$	epression High anxiety or depression N = 174		P-value
Age (years)	26.2 (6.95)	30.0 (6.87)	27.7 (7.16)	< 0.00
Isolation time until survey (days)	19.8 (7.63)	20.9 (7.77)	20.3 (7.70)	0.144
Confirmed time until survey (days)	12.1 (4.59)	13.0 (5.68)	12.5 (5.07)	0.074
Gender	12.1 (4.03)	13.0 (3.00)	12.0 (0.07)	< 0.00
Male	105 (41.5%)	30 (17.2%)	135 (31.6%)	<0.00
Female	148 (58.5%)	144 (82.8%)	292 (68.4%)	
Jobs	140 (00.070)	144 (02.070)	232 (00.470)	0.164
Manual labor	217 (85.8%)	161 (92.5%)	378 (88.5%)	0.104
Office staff	4 (1.58%)	2 (1.15%)	6 (1.41%)	
Student	12 (4.74%)	2 (1.15%)	14 (3.28%)	
Farmer				
Others	6 (2.37%)	4 (2.30%)	10 (2.34%) 19 (4.45%)	
Marital status	14 (5.53%)	5 (2.87%)	19 (4.45%)	0.001
	100 (41 00/)	40 (04 70/)	140 (04 00()	0.001
Single	106 (41.9%)	43 (24.7%)	149 (34.9%)	
Married/Domestic partnership	139 (54.9%)	126 (72.4%)	265 (62.1%)	
Divorced/Widowed/Separated	8 (3.16%)	5 (2.87%)	13 (3.04%)	0.000
Number of relatives with COVID-19			000 (7 (70()	0.002
None	173 (68.4%)	133 (76.4%)	306 (71.7%)	
1 person	33 (13.0%)	17 (9.77%)	50 (11.7%)	
2 persons	17 (6.72%)	19 (10.9%)	36 (8.43%)	
3 persons	9 (3.56%)	4 (2.30%)	13 (3.04%)	
≥4 persons	21 (8.30%)	1 (0.57%)	22 (5.15%)	
Level of education				0.024
University/Master/PhD/Doctoral	6 (2.37%)	2 (1.15%)	8 (1.87%)	
College	9 (3.56%)	4 (2.30%)	13 (3.04%)	
Vocational training	7 (2.77%)	2 (1.15%)	9 (2.11%)	
High school	129 (51.0%)	78 (44.8%)	207 (48.5%)	
Secondary school	91 (36.0%)	66 (37.9%)	157 (36.8%)	
Primary school	9 (3.56%)	21 (12.1%)	30 (7.03%)	
No formal education	2 (0.79%)	1 (0.57%)	3 (0.70%)	
Main income earner in the family				< 0.00
No	89 (35.2%)	26 (14.9%)	115 (26.9%)	
Yes	164 (64.8%)	148 (85.1%)	312 (73.1%)	
Average income (USD)				0.146
<130	15 (5.93%)	8 (4.60%)	23 (5.39%)	
130–220	71 (28.1%)	69 (39.7%)	140 (32.8%)	
220–440	161 (63.6%)	93 (53.4%)	254 (59.5%)	
440–660	3 (1.19%)	3 (1.72%)	6 (1.41%)	
660–880	2 (0.79%)	1 (0.57%)	3 (0.70%)	
>880	1 (0.40%)	0 (0.00%)	1 (0.23%)	
Isolation status				0.067
Voluntary	253 (100%)	171 (98.3%)	424 (99.3%)	
Forced	0 (0.00%)	3 (1.72%)	3 (0.70%)	
The enneagram personality				0.924
The reformer	3 (1.19%)	1 (0.57%)	4 (0.94%)	
The individualist	4 (1.58%)	2 (1.15%)	6 (1.41%)	
The investigator	2 (0.79%)	1 (0.57%)	3 (0.70%)	
The challenger	42 (16.6%)	22 (12.6%)	64 (15.0%)	
The enthusiast	19 (7.51%)	18 (10.3%)	37 (8.67%)	
The peacemaker	119 (47.0%)	82 (47.1%)	201 (47.1%)	
The achiever	1 (0.40%)	1 (0.57%)	2 (0.47%)	
The helper	57 (22.5%)	44 (25.3%)	101 (23.7%)	
The loyalist	6 (2.37%)	3 (1.72%)	9 (2.11%)	

Frontiers in Psychiatry | www.frontiersin.org

Predicting Psychological for COVID-19 Patients

TABLE 1 | (Continued)

	Low anxiety and depression	High anxiety or depression	Total	P-value	
	N = 253	<i>N</i> = 174 <i>N</i> = 427			
Personality changes				<0.001	
Irritability	24 (9.49%)	62 (35.6%)	86 (20.1%)		
No change	211 (83.4%)	110 (63.2%)	321 (75.2%)		
More peaceful	18 (7.11%)	2 (1.15%)	20 (4.68%)		
Review of facilities	4.12 (0.80)	3.91 (0.89)	4.04 (0.85)	0.016	
Review of living conditions	3.96 (0.85)	3.82 (0.92)	3.90 (0.88)	0.125	
Review of food	4.29 (0.76)	4.06 (0.89)	4.20 (0.82)	0.005	
Review of medical staff	4.44 (0.72)	4.29 (0.82)	4.38 (0.77)	0.059	
Medical camp review (points)	16.8 (2.75)	16.1 (3.15)	16.5 (2.94)	0.015	
Worried				0.072	
Family is stigmatized	7 (2.77%)	2 (1.15%)	9 (2.11%)		
No one to take care of children	4 (1.58%)	7 (4.02%)	11 (2.58%)		
Family finances are not secure	30 (11.9%)	27 (15.5%)	57 (13.3%)		
Personal health	156 (61.7%)	115 (66.1%)	271 (63.5%)		
Family health	38 (15.0%)	18 (10.3%)	56 (13.1%)		
Others	18 (7.11%)	5 (2.87%)	23 (5.39%)		

Questionnaire Design

The survey included 17 questions about the general characteristics of the patients, 15 questions to assess common symptoms, the Patient Health Questionnaire-9 (PHQ-9), and General Anxiety Disorder-7 (GAD-7) scores. Categories of depression symptoms were defined as low depression (PHQ-9 score 0-9) and high depression (PHQ-9 score \geq 10) (10). Categories of anxiety symptoms were defined as low anxiety (GAD-7 score 0-9) and high anxiety (GAD-7 score \geq 10) (11). The low anxiety and depression (LAD) group included patients with low anxiety or low depression. In contrast, the high anxiety and depression (HAD) group included patients with moderate and severe anxiety or moderate and severe depression (moderate or severe). Finally, the survey participants graded the medical camps based on four criteria: facilities, food, medical staff, and living conditions on a 5-level Likert scale (1: very poor; 5: very good).

Statistics Analysis

The Shapiro-Wilk test was conducted to test the normal distribution hypothesis for continuous variables. Comparisons were made using a *t*-test for continuous variables with normal distribution, and the Mann-Whitney U test for continuous variables with non-normal distribution. Data were presented as the number of patients (percent) for categorical variables. The Chi-square test (if the expected value in cell > 5) and the Fisher exact test (if the expected value in cell < 5) were conducted for categorical variables to compare baseline characteristics between the study groups (intervention and non-intervention). The correlation between Patient Health Questionnaire-9 and General Anxiety Disorder-7 was determined. Univariate and multivariate logistics regressions were conducted to evaluate the odds ratio (OR) and 95% confidence interval (95% CI) of factors between the intervention group and the nonintervention group. All hypotheses were tested as two tails, with

a *p*-value < 0.05 considered statistically significant. Statistical analyses were performed using RStudio version 3.6.2.

Ethical Consideration

The ethics committee approved all procedures of Traditional Medicine Hospital-Ministry of Public Security, Hanoi, Vietnam (No.664/QD-YHCT). Consent forms were attached to the survey questionnaire, and the patients only took the survey after accepting the terms of the study.

RESULTS

A total of 427 patients with COVID-19 participated in this study, with a response rate of 64.2%. Men made up 31.6% of the participants, while women made up 68.4%. The mean participant age was 27.7 (standard deviation = 7.16). Moreover, 174 patients (40.7%) were identified as HAD. **Figure 1** shows a positive correlation between PHQ-9 and GAD-7 scores. Specifically, the proportion of patients with a GAD-7 score greater than or equal to 10 and a PHQ-9 score less than 10 is relatively low.

According to **Table 1**, the mean age of the subjects in the HAD group was 30 (6.87), which was statistically significantly higher than in the LAD group, whose mean age was 26.2 (6.95). In the HAD group, 82.8% of the patients were women, compared to the 58.5% in the LAD group. Furthermore, in the HAD group, 85.1% of patients were defined as primary workers in the family, which was significantly higher than in the LAD group (68.4%). According to the personality changes criterion, the HAD group had a significantly higher rate of irritability; 35.6% compared to the 9.49% of the LAD group. The LAD group evaluated facilities, food, living conditions, and medical staff higher than the HAD group. In particular, statistical significance was found between the two groups in facilities (p-value = 0.016) and food (p-value = 0.005).

Predicting Psychological f	for COVID-19 Patients
----------------------------	-----------------------

TABLE 2 Symptoms of coronavirus disease 2019 (COVID-19) by anxiety and
depression status.

Number of symptoms 5.21 (3.44) 7.95 Body temperature 37.4 (0.86) 37.7 Asymptomatic Yes 23 (9.09%) 1 (0 No 230 (90.9%) 173 (0.86) 37.7 Asymptomatic Yes 230 (90.9%) 173 (0.86) Fever symptom No 230 (90.9%) 173 (0.86) No 141 (55.7%) 56 (3 Yes 112 (44.3%) 118 (0.60) Cough No 73 (28.9%) 38 (2.9%) No 73 (28.9%) 38 (2.9%) 38 (2.9%) Yes 180 (71.1%) 136 (0.9%) 316 (2.9%) Shortness of breath No 188 (74.3%) 81 (4.6%) 31 (0.9%) Yes 65 (25.7%) 93 (2.9%) 35 (53.6%) 93 (2.9%) Sore throat No 142 (56.1%) 14.0 (0.9%) 10.0 (142 (56.1%) 11.0 (1.9%) Headache No 135 (53.4%) 43 (2.9%) 136 (2.9%)	High anxiety or depression	Total	P-value	
Body temperature 37.4 (0.86) 37.7 Asymptomatic Yes 23 (9.09%) 1 (0) No 230 (90.9%) 173 (9) Fever symptom 112 (44.3%) 118 (0) Cough 112 (44.3%) 118 (0) No 73 (28.9%) 38 (2) Yes 180 (71.1%) 136 (0) Shortness of breath 110 (0) No 73 (28.9%) 38 (2) Yes 180 (71.1%) 136 (0) Shortness of breath 110 (0) No 142 (56.1%) 64 (2) Yes 111 (43.9%) 110 (0) Headache 110 (0) No 142 (56.1%) 64 (2) Yes 135 (53.4%) 143 (2) Yes 135 (53.4%) 143 (2) Yes 135 (53.4%) 43 (2) Yes 135 (53.4%) 43 (2) Yes 37 (14.6%) 66 (3) Joint pain 112 (1) 112 (1) No 168 (66.4%) 76 (4) Yes 37 (14.6%) 68 (2) Join	= 174	N = 427		
Asymptomatic Yes 23 (9.09%) 1 (0) No 230 (90.9%) 173 (s) Fever symptom	(3.34)	6.33 (3.65)	< 0.001	
Yes23 (9.09%) 1 (0No230 (90.9%) 173 (2)Fever symptom112No141 (55.7%) 56 (3)Yes112 (44.3%) 118 (0)Cough138 (74.3\%)81 (4)No188 (74.3%) 81 (4)Yes65 (25.7%) 93 (5)Shortness of breath110 (0)No142 (56.1%) 64 (3)Yes111 (43.9%) 110 (0)Headache111 (43.9%) 110 (0)No135 (53.4%) 43 (2)Yes135 (53.4%) 43 (2)Yes118 (46.6%) 31 (1)Yes135 (53.4%) 43 (2)Yes135 (53.4%) 43 (2)Yes135 (53.4%) 43 (2)Yes136 (66.4%) 76 (4)Yes138 (46.6%) 76 (4)Yes168 (66.4%) 76 (4)Yes33 (32.8%) 86 (2)Joint painNo168 (66.4%) 76 (4)No170 (67.2%) 88 (5)Joint painNo145 (57.3%) 66 (3)No145 (57.3%) 66 (3)86 (2)DiarrheaNo145 (57.3%) 66 (3)No145 (57.3%) 66 (3)86 (2)Yes170 (67.2%) 186 (2)Yes170 (67.2%) 136 (2)Loss of smellNo145 (57.3%) 66 (3)No145 (57.3%) 66 (3)Yes170 (67.2%) 136 (2)Yes170 (67.2%)	(0.93)	38.4 (15.9)	< 0.001	
No 230 (90.9%) 173 (0) Fever symptom 141 (55.7%) 56 (3) Yes 112 (44.3%) 118 (0) Cough 112 (44.3%) 118 (0) No 73 (28.9%) 38 (2) Yes 180 (71.1%) 136 (0) Shortness of breath 110 (0) No 188 (74.3%) 81 (4) Yes 65 (25.7%) 93 (5) Sore throat 110 (0) No 142 (56.1%) 64 (2) Yes 111 (43.9%) 110 (0) Headache 110 (0) 142 (56.1%) 64 (2) No 142 (56.1%) 143 (0) Muscle pain 110 (0) 144 (6.6%) 31 (1) Yes 135 (53.4%) 43 (2) Yes 135 (53.4%) 13 (2) Yes 118 (46.6%) 13 (1) Chest tightness 118 (46.6%) 13 (1) No 168 (66.4%) 76 (4) Yes 33 (32.8%) 86 (2) Joint pain 112 (1) 112 (1) No 170 (67.2%)			< 0.001	
Fever symptom Fever symptom No 141 (55.7%) 56 (3) Yes 112 (44.3%) 118 (1) Cough	.57%)	24 (5.62%)		
No $141 (55.7\%)$ $56 (3)$ Yes $112 (44.3\%)$ $118 (1)$ Cough	99.4%)	403 (94.4%)		
Yes 112 (44.3%) 118 (Cough 73 (28.9%) 38 (2 Yes 180 (71.1%) 136 (Shortness of breath 118 118 (No 188 (74.3%) 81 (4 Yes 65 (25.7%) 93 (5 Sore throat 110 (No 142 (56.1%) 64 (3 Yes 111 (43.9%) 110 (Headache 111 (43.9%) 110 (Headache 118 (46.6%) 31 (1 Yes 135 (53.4%) 43 (2 Yes 135 (53.4%) 43 (2 Yes 118 (46.6%) 131 (Chest tightness 118 (46.6%) 131 (No 168 (66.4%) 76 (4 Yes 85 (33.6%) 98 (5 Joint pain No 168 (66.4%) 76 (4 Yes 37 (14.6%) 62 (3 Diarrhea No 170 (67.2%) 88 (5 No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (4 Loss of taste No 145 (57.3%)			<0.001	
Cough 73 (28.9%) 38 (2 Yes 180 (71.1%) 136 (Shortness of breath 138 (74.3%) 81 (4 Yes 65 (25.7%) 93 (5 Sore throat 142 (56.1%) 64 (3 Yes 111 (43.9%) 110 (Headache 111 (43.9%) 110 (Headache 118 (46.6%) 31 (1 Yes 135 (53.4%) 143 (Muscle pain 135 (53.4%) 43 (2 Yes 118 (46.6%) 131 (Chest tightness 118 (46.6%) 131 (No 135 (53.4%) 43 (2 Yes 118 (46.6%) 131 (Chest tightness 118 (46.6%) 131 (No 135 (53.4%) 43 (2 Yes 37 (14.6%) 62 (3 Joint pain No 168 (66.4%) 76 (4 Yes 37 (14.6%) 62 (3 Diarthea No 170 (67.2%) 88 (5 Yes 108 (42.7%) 108 (4 Yes 108 (42.7%) 108 (4 Yes	32.2%)	197 (46.1%)		
No 73 (28.9%) 38 (2 Yes 180 (71.1%) 136 (7 Shortness of breath 138 (74.3%) 81 (4 Yes 65 (25.7%) 93 (5 Sore throat 111 (43.9%) 110 (7 Headache 111 (43.9%) 110 (7 Headache 118 (46.6%) 31 (1 Yes 135 (53.4%) 43 (2 Yes 135 (53.4%) 43 (2 Yes 135 (53.4%) 43 (2 Yes 138 (46.6%) 76 (4 Yes 138 (66.4%) 76 (4 Yes 138 (66.4%) 76 (4 Yes 85 (33.6%) 98 (5 Joint pain Vo 168 (66.4%) 76 (4 Yes 37 (14.6%) 62 (25 Joint pain Vo 216 (85.4%) 112 (10 Yes 37 (14.6%) 62 (25 Diarthea Vo 170 (67.2%) 88 (5 Yes 33 (32.8%) 86 (4 Loss of taste Vo 108 (1 <td>67.8%)</td> <td>230 (53.9%)</td> <td></td>	67.8%)	230 (53.9%)		
No $73 (28.9\%)$ $38 (2)$ Yes $180 (71.1\%)$ $136 (7)$ Shortness of breath $138 (74.3\%)$ $81 (4)$ Yes $65 (25.7\%)$ $93 (5)$ Sore throat $142 (56.1\%)$ $64 (3)$ Yes $111 (43.9\%)$ $110 (7)$ Headache $118 (46.6\%)$ $31 (1)$ Yes $135 (53.4\%)$ $143 (7)$ Muscle pain $135 (53.4\%)$ $43 (2)$ Yes $118 (46.6\%)$ $31 (1)$ Yes $135 (53.4\%)$ $43 (2)$ Yes $135 (53.4\%)$ $43 (2)$ Yes $118 (46.6\%)$ $131 (1)$ Chest tightness $112 (1)$ No $135 (53.4\%)$ $43 (2)$ Yes $31 (1) (1)$ $112 (1)$ Yes $31 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1$,	,	0.131	
Yes 180 (71.1%) 136 (Shortness of breath 188 (74.3%) 81 (4 No 188 (74.3%) 81 (4 Yes 65 (25.7%) 93 (5 Sore throat 93 (5 No 142 (56.1%) 64 (3 Yes 111 (43.9%) 110 (1 Headache 118 (46.6%) 31 (1 Yes 135 (53.4%) 43 (2 Yes 135 (53.4%) 43 (2 Yes 138 (46.6%) 143 (1 Muscle pain 100 118 (46.6%) 131 (1 Yes 135 (53.4%) 43 (2 Yes 136 (1 Yes 138 (66.4%) 76 (4 Yes 137 (1 136 (1 Chest tightness 118 (46.6%) 131 (1 131	21.8%)	111 (26.0%)		
Shortness of breath 81 (4 No 188 (74.3%) 81 (4 (res 65 (25.7%) 93 (5 Sore throat 93 93 No 142 (56.1%) 64 (3 rées 111 (43.9%) 110 (0 Headache 93 111 (43.9%) 110 (0 Headache 93 113 (10 (0 114 (46.6%)) 31 (1 Yes 135 (53.4%) 43 (2 113 (0 113 (0 Muscle pain 93 135 (53.4%) 43 (2 113 (0 Muscle pain 93 113 (10 (0	78.2%)	316 (74.0%)		
No $188 (74.3\%)$ $81 (4)$ Yes $65 (25.7\%)$ $93 (5)$ Sore throat $142 (56.1\%)$ $64 (3)$ Yes $111 (43.9\%)$ $110 (1)$ Headache $111 (43.9\%)$ $110 (1)$ Yes $135 (53.4\%)$ $143 (1)$ Yuscle pain $118 (46.6\%)$ $31 (1)$ Yes $135 (53.4\%)$ $43 (2)$ Yes $118 (46.6\%)$ $131 (1)$ Chest tightness $118 (46.6\%)$ $131 (1)$ Yo $168 (66.4\%)$ $76 (4)$ Yes $85 (33.6\%)$ $98 (5)$ Joint pain $112 (1)$ No $168 (66.4\%)$ $76 (4)$ Yes $37 (14.6\%)$ $62 (3)$ Diarrhea $112 (1)$ No $170 (67.2\%)$ $88 (5)$ Yes $33 (32.8\%)$ $66 (3)$ Yes $135 (57.3\%)$ $66 (3)$ Yes $108 (42.7\%)$ $108 (1)$ Loss of taste $108 (42.7\%)$ $108 (1)$ No $145 (57.3\%)$ $66 (3)$ Yes $108 (42.7\%)$ $108 (1)$ Loss of smell $108 (42.7\%)$ $136 (7)$ No $219 (90.5\%)$ $138 (7)$ Yes $229 (90.5\%)$ $138 (7)$ Yes $24 (9.49\%)$ $36 (2)$ Loss of ability to speak $108 (1)$ No $246 (97.2\%)$ $156 (7)$ Yes $7 (2.77\%)$ $18 (1)$	10.270)	010 (7 1.070)	<0.001	
Yes $65 (25.7\%)$ $93 (5)$ Sore throat $142 (56.1\%)$ $64 (3)$ No $142 (56.1\%)$ $64 (3)$ Yes $111 (43.9\%)$ $110 (1)$ Headache $111 (43.9\%)$ $110 (1)$ No $118 (46.6\%)$ $31 (1)$ Yes $135 (53.4\%)$ $43 (2)$ Muscle pain $118 (46.6\%)$ $113 (1)$ No $135 (53.4\%)$ $43 (2)$ Yes $135 (53.4\%)$ $43 (2)$ Yes $135 (53.4\%)$ $43 (2)$ Yes $118 (46.6\%)$ $131 (1)$ Chest tightness $118 (46.6\%)$ $131 (1)$ No $168 (66.4\%)$ $76 (4)$ Yes $85 (33.6\%)$ $98 (5)$ Joint pain $112 (1)$ No $216 (85.4\%)$ $112 (1)$ Yes $37 (14.6\%)$ $62 (3)$ Diarrhea $115 (57.3\%)$ $66 (3)$ No $145 (57.3\%)$ $66 (3)$ Yes $108 (42.7\%)$ $108 (1)$ Loss of taste $108 (42.7\%)$ $108 (1)$ No $81 (32.0\%)$ $38 (2)$ Yes $172 (68.0\%)$ $136 (1)$ Ko $229 (90.5\%)$ $138 (1)$ Yes $24 (9.49\%)$ $36 (2)$ Loss of ability to speak $100 (2) (2,7\%)$ $136 (1)$ No $246 (97.2\%)$ $156 (1)$ Yes $7 (2.77\%)$ $18 (1)$	16 6%)	260 (62 0%)	<0.001	
Sore throat 142 (56.1%) 64 (3) No 142 (56.1%) 64 (3) Yes 111 (43.9%) 110 (1) Headache $111 (43.9\%)$ 110 (1) Yes 135 (53.4%) 133 (1) Yes 135 (53.4%) 143 (2) Muscle pain $118 (46.6\%)$ 131 (1) No 135 (53.4%) 43 (2) Yes 118 (46.6%) 131 (1) Chest tightness $118 (46.6\%)$ 131 (1) No 168 (66.4%) 76 (4) Yes 85 (33.6%) 98 (5) Joint pain $112 (1)$ $112 (1)$ No 216 (85.4%) 112 (1) Yes 37 (14.6%) 62 (3) Diarrhea $112 (1)$ $112 (1)$ No 170 (67.2%) 88 (5) Yes 33 (32.8%) 86 (4) Loss of taste $100 (1)$ $100 (1)$ No 145 (57.3%) 66 (3) Yes 108 (42.7%) 108 (1) Loss of smell $100 (1)$ $100 (1)$ No 214 (32	,	269 (63.0%)		
No 142 (56.1%) 64 (3) Yes 111 (43.9%) 110 (0) Headache 111 (43.9%) 110 (0) No 118 (46.6%) 31 (1) Yes 135 (53.4%) 143 (2) Muscle pain 118 (46.6%) 143 (2) No 135 (53.4%) 43 (2) Yes 118 (46.6%) 131 (1) Chest tightness 118 (46.6%) 131 (1) Chest tightness 118 (46.6%) 131 (1) Chest tightness 112 (1) 112 (1) Yes 85 (33.6%) 98 (5) Joint pain No 216 (85.4%) 112 (1) Yes 37 (14.6%) 62 (3) Diarrhea No 170 (67.2%) 88 (6) Loss of taste No 145 (57.3%) 66 (3) Yes 108 (42.7%) 108 (4) Loss of smell No 145 (57.3%) 66 (3) Yes 172 (68.0%) 136 (1) Yes 172 (68.0%) 136 (2) <td< td=""><td>JJ.4 70)</td><td>158 (37.0%)</td><td>-0.004</td></td<>	JJ.4 70)	158 (37.0%)	-0.004	
Yes 111 (43.9%) 110 (Headache 118 (46.6%) 31 (1 No 118 (46.6%) 31 (1 Yes 135 (53.4%) 143 (Muscle pain 118 (46.6%) 31 (1 No 135 (53.4%) 143 (Muscle pain 118 (46.6%) 131 (1 No 135 (53.4%) 43 (2 Yes 118 (46.6%) 131 (1 Chest tightness 118 (46.6%) 131 (1 No 168 (66.4%) 76 (4 Yes 85 (33.6%) 98 (5 Joint pain No 168 (65.4%) 112 (1 No 216 (85.4%) 112 (1 Yes 37 (14.6%) 62 (3 Diarrhea No 170 (67.2%) 88 (5 Yes 83 (32.8%) 86 (4 Loss of taste No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (4 Loss of smell No 145 (57.3%) 66 (2 Yes 172 (68.0%) 136 (7 Yes 129 (90.5%) 138 (7 <		000 (40 00)	<0.001	
Headache 31 (1 No 118 (46.6%) 31 (1 Yes 135 (53.4%) 143 (2 Muscle pain 35 (53.4%) 43 (2 Yes 118 (46.6%) 131 (1 No 135 (53.4%) 43 (2 Yes 118 (46.6%) 131 (1 Chest tightness 118 (46.6%) 131 (1 No 135 (53.4%) 43 (2 Yes 118 (46.6%) 131 (1 Chest tightness 118 (46.6%) 131 (1 No 168 (66.4%) 76 (4 Yes 85 (33.6%) 98 (5 Joint pain No 216 (85.4%) 112 (1 Yes 37 (14.6%) 62 (3 Diarrhea No 170 (67.2%) 88 (5 Yes 83 (32.8%) 86 (4 Loss of taste No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (4 Loss of smell No 145 (57.3%) 66 (3 Yes 172 (68.0%) 136 (7 Ko 229 (90.5%) 138 (7 Yes	,	206 (48.2%)		
No 118 (46.6%) 31 (1 Yes 135 (53.4%) 143 (2 Muscle pain	63.2%)	221 (51.8%)		
Yes 135 (53.4%) 143 (Muscle pain 135 (53.4%) 43 (2 Yes 118 (46.6%) 131 (Chest tightness 118 (46.6%) 131 (No 168 (66.4%) 76 (4 Yes 85 (33.6%) 98 (5 Joint pain 112 (r No 216 (85.4%) 112 (r Yes 37 (14.6%) 62 (3 Diarrhea No 170 (67.2%) 88 (5 Yes 83 (32.8%) 86 (4 Loss of taste No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (r Loss of smell No 81 (32.0%) 38 (2 No 81 (32.0%) 38 (2 Yes 126 (2 Sys 172 (68.0%) 136 (7 Red eyes 136 (2 No 229 (90.5%) 138 (7 Yes 24 (9.49%) 36 (2 Loss of ability to speak No 246 (97.2%) 156 (7 Yes 7 (2.77%) 18 (1 Yes 156 (7			<0.001	
Muscle pain 135 (53.4%) 43 (2 Yes 118 (46.6%) 131 (Chest tightness 118 (46.6%) 131 (No 168 (66.4%) 76 (4 Yes 85 (33.6%) 98 (5 Joint pain 112 (r No 216 (85.4%) 112 (r Yes 37 (14.6%) 62 (3 Diarthea 112 (r No 170 (67.2%) 88 (5 Yes 83 (32.8%) 86 (4 Loss of taste 108 (42.7%) 108 (r No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (r Loss of smell 108 (42.7%) 136 (r No 81 (32.0%) 38 (2 Yes 172 (68.0%) 136 (r Loss of smell 108 (r 138 (r No 229 (90.5%) 138 (r Yes 24 (9.49%) 36 (2 Loss of ability to speak 108 (r No 246 (97.2%) 156 (r Yes 7 (2.77%) 18 (r	17.8%)	149 (34.9%)		
No 135 (53.4%) 43 (2 Yes 118 (46.6%) 131 (Chest tightness 1 1 No 168 (66.4%) 76 (4 Yes 85 (33.6%) 98 (5 Joint pain 1 1 No 216 (85.4%) 112 (1 Yes 37 (14.6%) 62 (3 Diarrhea 1 1 No 170 (67.2%) 88 (5 Yes 83 (32.8%) 86 (4 Loss of taste 1 1 No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (1 Loss of smell 1 1 No 145 (57.3%) 66 (3 Yes 172 (68.0%) 136 (1 Loss of smell 1 1 No 229 (90.5%) 138 (1 Yes 24 (9.49%) 36 (2 Loss of ability to speak 1 1 No 246 (97.2%) 156 (1 Yes 7 (2.77%) 18 (1	82.2%)	278 (65.1%)		
Yes 118 (46.6%) 131 (Chest tightness 118 (46.6%) 76 (4 Yes 85 (33.6%) 98 (5 Joint pain 112 (r No 216 (85.4%) 112 (r Yes 37 (14.6%) 62 (3 Diarrhea 112 (r No 170 (67.2%) 88 (5 Yes 83 (32.8%) 86 (4 Loss of taste 108 (42.7%) 108 (r No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (r Loss of smell 108 (42.7%) 108 (r No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (r Loss of smell 108 (42.7%) 136 (r No 24 (9.0%) 36 (2 Yes 172 (68.0%) 136 (r Yes 24 (9.49%) 36 (2 Loss of ability to speak 108 (r No 246 (97.2%) 156 (r Yes 7 (2.77%) 18 (r			< 0.001	
Chest tightness 76 (4 Yes 85 (33.6%) 98 (5) Joint pain 98 (5) No 216 (85.4%) 112 (1) Yes 37 (14.6%) 62 (3) Diarrhea 98 60 No 170 (67.2%) 88 (5) Yes 83 (32.8%) 86 (4) Loss of taste 98 108 (42.7%) No 145 (57.3%) 66 (3) Yes 108 (42.7%) 108 (4) Loss of smell 98 108 (42.7%) No 145 (57.3%) 66 (3) Yes 172 (68.0%) 136 (7) Yes 172 (68.0%) 136 (7) Yes 24 (9.49%) 36 (2) Loss of ability to speak 100 (2) 100 (2) Yes 24 (9.49%) 36 (2) Loss of ability to speak 103 (2) 103 (2)	24.7%)	178 (41.7%)		
No 168 (66.4%) 76 (4 Yes 85 (33.6%) 98 (5 Joint pain 98 98 No 216 (85.4%) 112 (1 Yes 37 (14.6%) 62 (3 Diarrhea 98 66 No 170 (67.2%) 88 (5 Yes 83 (32.8%) 86 (4 Loss of taste 98 98 No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (4 Loss of smell 98 98 No 81 (32.0%) 38 (2 Yes 172 (68.0%) 136 (1 Red eyes 229 (90.5%) 138 (1 No 229 (90.5%) 138 (1 Yes 24 (9.49%) 36 (2 Loss of ability to speak 108 No 246 (97.2%) 156 (1 Yes 7 (2.77%) 18 (1	75.3%)	249 (58.3%)		
Yes 85 (33.6%) 98 (5) Joint pain 98 (5) No 216 (85.4%) 112 (1) Yes 37 (14.6%) 62 (3) Diarrhea 98 60 No 170 (67.2%) 88 (5) Yes 83 (32.8%) 86 (4) Loss of taste 98 No 145 (57.3%) 66 (3) Yes 108 (42.7%) 108 (4) Loss of smell 108 108 (42.7%) No 145 (57.3%) 66 (3) Yes 108 (42.7%) 108 (4) Loss of smell 108 (42.7%) 108 (4) No 81 (32.0%) 38 (2) Yes 172 (68.0%) 136 (7) Red eyes 108 112 (1) No 229 (90.5%) 138 (7) Loss of ability to speak 108 1136 (7) Loss of ability to speak 108 108 No 246 (97.2%) 156 (7) Yes 7 (2.77%) 18 (1)			< 0.001	
Joint pain 216 (85.4%) 112 (r No 216 (85.4%) 112 (r Yes 37 (14.6%) 62 (s Diarrhea 5 No 170 (67.2%) 88 (s Yes 83 (32.8%) 86 (a Loss of taste 5 66 (s Yes 108 (42.7%) 108 (b Loss of smell 5 108 (42.7%) No 145 (57.3%) 66 (s Yes 108 (42.7%) 108 (b Loss of smell 5 108 (42.7%) No 81 (32.0%) 38 (z Yes 172 (68.0%) 136 (c Red eyes 7 138 (c No 229 (90.5%) 138 (c Loss of ability to speak 5 No 246 (97.2%) 156 (c Yes 7 (2.77%) 18 (t	13.7%)	244 (57.1%)		
No 216 (85.4%) 112 (r Yes 37 (14.6%) 62 (3 Diarrhea 9 No 170 (67.2%) 88 (5 Yes 83 (32.8%) 86 (4 Loss of taste 9 No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (6 Loss of smell 9 108 (42.7%) No 81 (32.0%) 38 (2 Yes 172 (68.0%) 136 (7 Red eyes 12 9 No 229 (90.5%) 138 (7 Vo 229 (90.5%) 138 (7 Kes 24 (9.49%) 36 (2 Loss of ability to speak 108 No 246 (97.2%) 156 (7 Yes 7 (2.77%) 18 (1	56.3%)	183 (42.9%)		
Yes 37 (14.6%) 62 (3) Diarrhea 70 (67.2%) 88 (5) Yes 83 (32.8%) 86 (4) Loss of taste 8 8 No 145 (57.3%) 66 (3) Yes 108 (42.7%) 108 (4) Loss of smell 108 (42.7%) 108 (4) No 81 (32.0%) 38 (2) Yes 172 (68.0%) 136 (1) Red eyes 108 138 (2) No 229 (90.5%) 138 (2) Yes 24 (9.49%) 36 (2) Loss of ability to speak 100 100 (2) No 246 (97.2%) 156 (1) Yes 7 (2.77%) 18 (1)			< 0.001	
Diarrhea No 170 (67.2%) 88 (5 Yes 83 (32.8%) 86 (4 Loss of taste 108 (42.7%) 66 (3 Yes 108 (42.7%) 108 (4 Loss of smell 108 (42.7%) 108 (4 No 81 (32.0%) 38 (2 Yes 172 (68.0%) 136 (1 Red eyes 108 108 (1 No 229 (90.5%) 138 (1 Yes 24 (9.49%) 36 (2 Loss of ability to speak 100 100 (1 No 246 (97.2%) 156 (1 Yes 7 (2.77%) 18 (1	64.4%)	328 (76.8%)		
No 170 (67.2%) 88 (5 Yes 83 (32.8%) 86 (4 Loss of taste 1 1 No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (4 Loss of smell 1 1 No 81 (32.0%) 38 (2 Yes 172 (68.0%) 136 (1 Red eyes 1 1 No 229 (90.5%) 138 (1 Yes 24 (9.49%) 36 (2 Loss of ability to speak 1 1 No 246 (97.2%) 156 (1 Yes 7 (2.77%) 18 (1	35.6%)	99 (23.2%)		
No 170 (67.2%) 88 (5 Yes 83 (32.8%) 86 (4 Loss of taste 1 1 No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (4 Loss of smell 1 1 No 81 (32.0%) 38 (2 Yes 172 (68.0%) 136 (1 Red eyes 1 1 No 229 (90.5%) 138 (1 Yes 24 (9.49%) 36 (2 Loss of ability to speak 1 1 No 246 (97.2%) 156 (1 Yes 7 (2.77%) 18 (1	,	, ,	0.001	
Yes 83 (32.8%) 86 (4 Loss of taste	50.6%)	258 (60.4%)		
Loss of taste 145 (57.3%) 66 (3) Yes 108 (42.7%) 108 (6) Loss of smell 108 (42.7%) 108 (6) No 81 (32.0%) 38 (2) Yes 172 (68.0%) 136 (7) Red eyes 229 (90.5%) 138 (7) Yes 24 (9.49%) 36 (2) Loss of ability to speak 100 156 (7) Yes 7 (2.77%) 18 (1)	19.4%)	169 (39.6%)		
No 145 (57.3%) 66 (3 Yes 108 (42.7%) 108 (0 Loss of smell 108 108 (42.7%) No 81 (32.0%) 38 (2 Yes 172 (68.0%) 136 (7 Red eyes 229 (90.5%) 138 (7 No 229 (90.5%) 138 (7 Yes 24 (9.49%) 36 (2 Loss of ability to speak 108 No 246 (97.2%) 156 (7 Yes 7 (2.77%) 18 (1			<0.001	
Yes 108 (42.7%) 108 (Loss of smell 108 (No 81 (32.0%) 38 (2 Yes 172 (68.0%) 136 (Red eyes 108 (108 (No 229 (90.5%) 138 (Yes 24 (9.49%) 36 (2 Loss of ability to speak 108 (No 246 (97.2%) 156 (Yes 7 (2.77%) 18 (1	87.0%)	211 (49.4%)	<0.001	
Loss of smell 81 (32.0%) 38 (2 Yes 172 (68.0%) 136 (Red eyes 1 1 No 229 (90.5%) 138 (Yes 24 (9.49%) 36 (2 Loss of ability to speak 1 1 No 246 (97.2%) 1 1 Yes 7 (2.77%) 18 (1	,	216 (50.6%)		
No 81 (32.0%) 38 (2 Yes 172 (68.0%) 136 (Red eyes 1 1 No 229 (90.5%) 138 (Yes 24 (9.49%) 36 (2 Loss of ability to speak 1 No 246 (97.2%) 156 (2 Yes 7 (2.77%) 18 (1	02.170)	210 (30.070)	0.000	
Yes 172 (68.0%) 136 (Red eyes 172 (68.0%) 138 (No 229 (90.5%) 138 (Yes 24 (9.49%) 36 (2 Loss of ability to speak 100 No 246 (97.2%) 156 (Yes 7 (2.77%) 18 (1		110 (07 00()	0.028	
Red eyes 229 (90.5%) 138 (Yes 24 (9.49%) 36 (2 Loss of ability to speak 4 No 246 (97.2%) 156 (2 Yes 7 (2.77%) 18 (1	,	119 (27.9%)		
No 229 (90.5%) 138 (Yes 24 (9.49%) 36 (2 Loss of ability to speak No 246 (97.2%) 156 (Yes 7 (2.77%) 18 (1	78.2%)	308 (72.1%)		
Yes 24 (9.49%) 36 (2 Loss of ability to speak Xo 246 (97.2%) 156 (2 Yes 7 (2.77%) 18 (1			0.002	
Loss of ability to speak No 246 (97.2%) 156 (r Yes 7 (2.77%) 18 (1	79.3%)	367 (85.9%)		
No 246 (97.2%) 156 (Yes 7 (2.77%) 18 (1	20.7%)	60 (14.1%)		
Yes 7 (2.77%) 18 (1			0.002	
	89.7%)	402 (94.1%)		
Rash	10.3%)	25 (5.85%)		
luon			0.016	
No 220 (87.0%) 135 (77.6%)	355 (83.1%)		
Yes 33 (13.0%) 39 (2	22.4%)	72 (16.9%)		
Nausea/vomiting			<0.001	
•	59.8%)	309 (72.4%)		
	10.2%)	118 (27.6%)		

The HAD group had a significantly higher rate of symptoms than the LAD group, except for cough symptoms. According to **Table 2**, asymptomatic patients in the LAD group were 9.09%, approximately 16 times higher than in the HAD group. However, the difference between the two groups was not statistically significant in terms of cough symptoms (p = 0.131).

As shown in Table 3, HAD status was significantly higher among older patients, women, main income earners, and those suffering from shortness of breath, headaches, joint pain, and loss of speaking ability. Moreover, patients with loss of speaking ability have higher odd ratios of needing interventions than patients without this loss (OR = 1.39; 95% CI = 1.15-1.70). Besides these factors, hospitals with higher review scores had fewer patients in the HAD group (OR = 0.98; 95% CI = 0.96-1). According to the results of multiple binary logistic regression analysis evaluating the risk factors in need of intervention, lower hospital review scores (OR = 0.98; 95% CI = 0.97-0.99) were found to be a risk for needing intervention, while older patients (OR = 1.1; 95% CI = 1.03-1.18), women (OR = 1.31; 95% CI = 1.09-1.31), patients who were main income earners (OR = 1.15; 95% CI = 1.03 - 1.28), patients who had headaches (OR = 1.16; 95% CI = 1.06-1.21), and patients who had joint pain (OR = 1.17; 95% CI = 1.06-1.3) were identified as risk factors for HAD status.

DISCUSSION

In the face of complicated developments of the COVID-19 epidemic in Vietnam, the government has taken an uncompromising approach to the centralized isolation of all confirmed cases. The measure has shown apparent effectiveness in controlling the COVID-19 outbreak. However, our study showed that the isolation process significantly impacted mental health. Symptoms of COVID-19 were positively correlated with depression and anxiety. Our study showed that age, confirmed cases until the survey, gender, being primary income earners, shortness of breath, headaches, joint pain, and loss of speaking ability were significantly associated with the likelihood of having HAD status. Furthermore, the medical camp review was significantly associated with reduction in LAD status. Our study points to the necessity of depression and anxiety treatment, such as psychological consultations, as well as the establishment of a policy to financially support low-income patients with COVID-19.

A previous study from Kong et al. (12) showed that the PHQ-9 and GAD-7 scales increase with age for COVID-19 patients. Our findings indicate that every 10-year increase in age was associated with a 10% increase in the likelihood of HAD status. The 1-week increase after the confirmation of COVID-19 was associated with a 4% increased likelihood of having HAD status. These results were similar to Yanyu Hu's study, which showed that the duration of COVID-19 was associated with a statistically significant increase in GAD-7 and PHQ-9 scores (13). Our results also showed that being female was associated with a 20% increased likelihood of having HAD status. This is similar to a previous study showing that women

Variables	Univariate analysis		Multivariable analysis	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age (10 years)	1.20 (1.12–1.28)	<0.001	1.10 (1.03–1.18)	0.006
Confirmed time until survey (weeks)	1.06 (1.00–1.13)	0.063	1.04 (0.99–1.11)	0.137
Hospital review (points)	0.98 (0.96-1.00)	0.013	0.98 (0.97-0.99)	0.007
Gender				
Male	Reference		Reference	
Female	1.31 (1.19–1.44)	<0.001	1.20 (1.09–1.31)	< 0.001
Main income earner in the family				
No	Reference		Reference	
Yes	1.28 (1.16-1.42)	<0.001	1.15 (1.03–1.28)	0.010
Shortness of breath				
No	Reference		Reference	
Yes	1.33 (1.21–1.46)	<0.001	1.10 (1.00-1.21)	0.060
Headache				
No	Reference		Reference	
Yes	1.36 (1.24–1.49)	<0.001	1.16 (1.06–1.28)	0.002
Joint pain				
No	Reference		Reference	
Yes	1.33 (1.19–1.48)	<0.001	1.17 (1.06–1.30)	0.003
Loss of ability to speak				
No	Reference		Reference	
Yes	1.39 (1.15–1.70)	0.001	1.19 (0.99–1.42)	0.061

with COVID-19 have higher depression and anxiety scores than men (14–17).

In the multivariate logistics regression results, the common symptoms of shortness of breath, headaches, and joint pain were significant factors related to the HAD group. Furthermore, study subjects being primary income earners were also associated with a 15% increased risk of having HAD status. Healthcare workers also have an increased chance of exposure to COVID-19 (18). This study showed that a decrease in family income due to COVID-19 led to an increase in high-level anxiety/depression status (19). In other studies, asymptomatic patients at the time of testing accounted for 30.8–51.7% (20, 21); this rate differed from our study (5.62%). However, follow-up studies over time show that the proportion of asymptomatic patients was much lower at about 10.7 (22) to 15.6% (23). This difference could be explained by patients being diagnosed at an early stage when they were not showing any symptoms.

Furthermore, a 1-point increase in the medical camp review was associated with a 2% reduction in the likelihood of having HAD status. During the isolation period, patients with COVID-19 shared a small space with limited facilities with other patients with COVID-19. Therefore, it was not surprising that their satisfaction with the medical camp was significantly associated with reduction in HAD status.

There were some limitations to our study. First, although this study was a random selection of patients through an online format, most of the participants were relatively young (mean age was 27.7); thus, it is necessary to investigate with an older participant pool. Second, there is a lack of follow-up in the study design related to depression and anxiety. Follow-up studies would clarify participants' levels of depression and anxiety after being COVID-19-free. Third, this study was conducted based on a self-reported questionnaire, which may involve respondents' bias.

CONCLUSION

This study indicated that increase in age would increase the likelihood of HAD. The advantage of medical camp has reduced the severity of shortage number of beds in the hospital, low-cost facilities and easy to establish. Moreover, low income and being a primary income earner also increased the risk of having HAD status. Government and policymakers should, thus, offer financial support for lowincome patients with COVID-19. Our study further showed that HAD status was correlated with increase in symptoms of COVID-19. Therefore, psychological consultations in Vietnam's medical camps are necessary to improve patient health conditions.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The Ethics Committee approved all procedures of Traditional Medicine Hospital–Ministry of Public Security, Hanoi, Vietnam (No.664/QD-YHCT). The patients/participants provided their written informed consent to participate in this study.

REFERENCES

- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33. doi: 10.1056/NEJMoa2001017
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
- Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. (2020) 382:2081–90. doi: 10.1056/NEJM0a2008457
- Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. *Trends Immunol.* (2020) 41:1100–15. doi: 10.1016/j.it.2020.10. 004
- Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency. *Sci Total Environ.* (2020) 730:138996. doi: 10.1016/j.scitotenv.2020.138996
- Mallah SI, Ghorab OK, Al-Salmi S, Abdellatif OS, Tharmaratnam T, Iskandar MA, et al. COVID-19: breaking down a global health crisis. *Ann Clin Microbiol Antimicrob.* (2021) 20:35. doi: 10.1186/s12941-021-00438-7
- Bac Giang Department of Information and Communication. Report: Summary of COVID-19 Prevention and Control in Bac Giang Province (237/BC-BCD). (2021). Available online at: https://stttt.bacgiang.gov.vn/ documents/21475/11798496/163333534577_BC-237.pdf/cfb3182d-5a4f-4372-98b5-f1595c9379cd (accessed June 6, 2021).
- Saltzman LY, Hansel TC, Bordnick PS. Loneliness, isolation, and social support factors in post-COVID-19 mental health. *Psychol Trauma*. (2020) 12(Suppl. 1):S55–7. doi: 10.1037/tra0000703
- Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: systematic review of the current evidence. *Brain Behav Immun.* (2020) 89:531–42. doi: 10.1016/j.bbi.2020.05.048
- Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the patient health questionnaire (PHQ-9): a meta-analysis. CMAJ Can Med Assoc J. (2012) 184:E191–6. doi: 10.1503/cmaj.110829
- Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med.* (2006) 166:1092–7. doi: 10.1001/archinte.166.10.1092
- Kong X, Zheng K, Tang M, Kong F, Zhou J, Diao L, et al. Prevalence and factors associated with depression and anxiety of hospitalized patients with COVID-19. *MedRxiv* [Preprint]. (2020). doi: 10.1101/2020.03.24.20043075
- Hu Y, Chen Y, Zheng Y, You C, Tan J, Hu L, et al. Factors related to mental health of inpatients with COVID-19 in Wuhan. China. *Brain Behav Immun.* (2020) 89:587–93. doi: 10.1016/j.bbi.2020.07.016
- Nie XD, Wang Q, Wang MN, Zhao S, Liu L, Zhu YL, et al. Anxiety and depression and its correlates in patients with coronavirus disease 2019 in Wuhan. *Int J Psychiatry Clin Pract.* (2021) 25:109–14. doi: 10.1080/13651501. 2020.1791345
- 15. Guo Q, Zheng Y, Shi J, Wang J, Li G, Li C, et al. Immediate psychological distress in quarantined patients with COVID-19 and its association with

AUTHOR CONTRIBUTIONS

KH, VT, and LV developed the study concept and provided critical revisions. KH, VT, LV, HT, MN, and HN performed the analysis. All authors contributed to draft the manuscript and to the study design and approved the final version of the manuscript for submission.

peripheral inflammation: a mixed-method study. *Brain Behav Immun.* (2020) 88:17–27. doi: 10.1016/j.bbi.2020.05.038

- Htun YM, Thiha K, Aung A, Aung NM, Oo TW, Win PS, et al. Assessment of depressive symptoms in patients with COVID-19 during the second wave of epidemic in Myanmar: a cross-sectional single-center study. *PLoS One.* (2021) 16:e0252189. doi: 10.1371/journal.pone.0252189
- Basheti IA, Mhaidat QN, Mhaidat HN. Prevalence of anxiety and depression during COVID-19 pandemic among healthcare students in Jordan and its effect on their learning process: a national survey. *PLoS One.* (2021) 16:e0249716. doi: 10.1371/journal.pone.0249716
- Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, et al. Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. (2020) 71:748–55. doi: 10.1093/cid/ciaa243
- Tran BX, Nguyen HT, Le HT, Latkin CA, Pham HQ, Vu LG, et al. Impact of COVID-19 on economic well-being and quality of life of the vietnamese during the National social distancing. *Front Psychol.* (2020) 11:565153. doi: 10.3389/fpsyg.2020.565153
- Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility – King County, Washington, March 2020. MMWR Morb Mort Wkly Rep. (2020) 69:377–81. doi: 10.15585/mmwr. mm6913e1
- Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. (2020) 94:154–5. doi: 10.1016/j.ijid.2020. 03.020
- Ki M, Task Force for 2019-nCoV. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. *Epidemiol Health.* (2020) 42:e2020007. doi: 10.4178/epih.e2020007
- He J, Guo Y, Mao R, Zhang J. Proportion of asymptomatic coronavirus disease 2019: a systematic review and meta-analysis. J Med Virol. (2021) 93:820–30. doi: 10.1002/jmv.26326

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Trang, Huynh, Truong, Nguyen, Hoang, Dao, Van Vu, Hassan, Nguyen and Truong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.